Sleep Leaders Support Efforts To Raise Awareness Of Untreated Sleep Apnea In The Medical Community
Philips Respironics and ResMed Inc. are joined by Cephalon Inc. to fund second year of Continuing Medical Education program
SleepApneaDisorder/[Press Release]/Murrysville, Pa., San Diego, Ca., and Frazer, Pa. USA – Philips Respironics, a unit of Royal Philips Electronics (NYSE: PHG, AEX: PHI), ResMed Inc. (NYSE: RMD and ASX: RMD.AX), and biopharmaceutical company, Cephalon Inc. (NASDAQ: CEPH), are supporting efforts to bring untreated sleep apnea to the forefront of discussion among primary care physicians (PCP). As the program enters its second year, Cephalon joins the device makers in responding to educational grant requests to fund a series of independent continuing medical education (CME) activities on this important topic.
“We are committed to lending our support to the sleep community to further awareness and physician understanding of the medical consequences of untreated sleep apnea,” explains Eoghan O’Lionaird, General Manager-Sleep for Philips Respironics. “CME programs are a critical component in bridging the gap for this growing public health issue.” Read the rest of this entry

















